FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for the fixed-dose combination of dapagliflozin and metformin hydrochloride, developed by Prasco Laboratories.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin and metformin hydrochloride (dapagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)